- Home
- ASTH
as 01-21-2025 4:00pm EST
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALHAMBRA |
| Market Cap: | 2.0B | IPO Year: | N/A |
| Target Price: | $66.40 | AVG Volume (30 days): | 384.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.30 | EPS Growth: | 34.92 |
| 52 Week Low/High: | $29.08 - $63.20 | Next Earning Date: | 02-25-2025 |
| Revenue: | $1,722,367,000 | Revenue Growth: | 29.71% |
| Revenue Growth (this year): | 46.11% | Revenue Growth (next year): | 34.25% |
Latest Astrana Health Inc. Common Stock News
ASTH Breaking Stock News: Dive into ASTH Ticker-Specific Updates for Smart Investing
PR Newswire
18 hours ago
Astrana Health, Inc. Announces Share Repurchase of 300,000 Shares
Simply Wall St.
6 days ago
Is Astrana Health, Inc. (NASDAQ:ASTH) Potentially Undervalued?
Argus Research
7 days ago
ASTH: What does Argus have to say about ASTH?
The Wall Street Journal
13 days ago
Prospect Medical Explores Restructuring
Simply Wall St.
23 days ago
With 52% ownership, Astrana Health, Inc. (NASDAQ:ASTH) boasts of strong institutional backing
Argus Research
a month ago
ASTH: Lowering target price to $35.00
PR Newswire
a month ago
Astrana Health, Inc. to Participate in Upcoming Investor Conference
Argus Research
a month ago
ASTH: Lowering target price to $37.00
Compare ASTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASTH Astrana Health Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.